World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Burmese Prescription Translation Demand Surges 300%, Signaling Shift in U.S. LEP Pharmacy Care

Cision PR Newswire by Cision PR Newswire
June 4, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

New Q1 2026 analysis from RxTran reveals accelerating demand for Asian and Middle Eastern language prescription translations

BOSTON, June 4, 2026 /PRNewswire/ — Demand for Burmese-language prescription label translations increased more than 300 percent from Q1 2025 to Q1 2026, according to new proprietary data released today by RxTran, a division of Language Scientific. The findings reflect a broader shift in the linguistic needs of Limited English Proficiency (LEP) pharmacy patients across the United States, with Asian and Middle Eastern language requests rising sharply while demand for several major European languages declined.

RxTran, a division of Language Scientific, Inc., delivers 100% accurate native-language prescription medication labeling in 26 languages through its patented Transduction technology.

RxTran’s analysis of prescription label translation requests across its national pharmacy network found that Pashto increased 60 percent year-over-year, Farsi rose 52 percent, and Vietnamese climbed 49 percent. By contrast, French-language requests fell 20 percent over the same period, and Armenian declined more than 16 percent. The data mirrors demographic trends reported by the U.S. Census Bureau, which has documented sustained growth in South and Southeast Asian and Middle Eastern immigrant communities in recent years.

The findings carry direct implications for pharmacy compliance and patient safety. Patient non-adherence to prescription directives, often driven by language barriers, accounts for approximately 22 percent of all hospitalizations annually in the United States. Federal law under Title VI of the Civil Rights Act and Section 1557 of the Affordable Care Act requires health care providers receiving federal funding to offer language access services to LEP patients, and an increasing number of states have enacted pharmacy-specific translation mandates.

“These trends are a direct reflection of the communities pharmacies serve today,” said Sharon Blank, Chief Executive Officer of Language Scientific and RxTran. “As the U.S. LEP population continues to grow and diversify, pharmacies that rely on static language coverage are leaving patients behind and exposing themselves to compliance risk. RxTran’s data gives the pharmacy industry an early signal of where those gaps are opening so they can act before a patient is harmed or a regulator takes notice.”

The analysis is drawn from RxTran’s proprietary translation database, which processes prescription SIG (patient instruction) translations across 26 languages through its patented Transduction technology. The platform integrates directly with major national pharmacy management systems and delivers regulatory-compliant translated labels at the point of dispensing. RxTran’s Transduction technology is covered by U.S. Patent No. 11,836,454 and additional pending applications.

This release marks the sixth installment in RxTran’s ongoing proprietary data series, launched in August 2024 to bring greater transparency to language access trends in U.S. pharmacy care.

About RxTran
RxTran is a division of Language Scientific, Inc., the clinical, medical, and scientific language specialists. RxTran’s patented Transduction technology provides 100% accurate native-language prescription medication labeling in 26 languages. For more information visit https://www.languagescientific.com/ or www.rxtran.com. 

Media Contact
RxTran@supremecomms.ai

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/burmese-prescription-translation-demand-surges-300-signaling-shift-in-us-lep-pharmacy-care-302791228.html

SOURCE RxTran

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Costero Brokers Appoints Jen Mahoney to its Board of Directors

    0 shares
    Share 0 Tweet 0
  • Waterdrop Inc. to Report Third Quarter 2026 Financial Results on December 2, 2026

    0 shares
    Share 0 Tweet 0
  • MAIRE: Nextchem (MAIRE) to acquire LNG process technologies from Chart Industries for $220 million

    0 shares
    Share 0 Tweet 0
  • ALMIS International selected by Afin Bank to power Basel 3.1 compliance and balance sheet transformation

    0 shares
    Share 0 Tweet 0
  • Tencent Music Entertainment Group Announces Third Quarter 2026 Unaudited Financial Results

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler